Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EYA3 | Q99504 | 6/20 | 1.00 |
| ▸ | TTR | P02766 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | PGR | P06401 | 2/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | PDE4A | P27815 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19688950 | 0.96 | EYA3 (0.92) | EYA3TTRMEN1ABCB11LMNA | |
| SCHEMBL25389973 | 0.92 | EYA3 (0.85) | EYA3TTRMEN1ABCB11LMNA | |
| SCHEMBL15698071 | 0.88 | EYA3 (1.00) | EYA3TTRMEN1ABCB11LMNA | |
| SCHEMBL15698032 | 0.84 | EYA3 (0.84) | EYA3TTRMEN1ABCB11LMNA | |
| SCHEMBL19214707 | 0.84 | EYA3 (0.91) | EYA3TTRMEN1ABCB11LMNA | |
| SCHEMBL7752224 | 0.83 | EYA3 (0.74) | EYA3TTRMEN1ABCB11LMNA | |
| SCHEMBL6335384 | 0.83 | EYA3 (1.00) | EYA3TTRMEN1ABCB11LMNA | |
| Benziodarone SCHEMBL308541 | 0.83 | EYA3 (1.00) | EYA3TTRMEN1ABCB11LMNA | |
| Benziodarone SCHEMBL31326233 | 0.83 | EYA3 (1.00) | EYA3TTRMEN1ABCB11LMNA | |
| SCHEMBL25389746 | 0.82 | EYA3 (0.73) | EYA3TTRMEN1ABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | CHILDRENS HOSPITAL MED CT (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2019195118-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-10-10 | — | — | WO | disclosed |
| US-10221151-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER | 2017-12-07 | — | — | US | disclosed |
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER | 2017-12-07 | — | — | US | disclosed |
| US-9725430-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725430-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160052904-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-25 | — | — | US | disclosed |
| US-20160052904-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349562-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | EYA2, EYA3, PTPRO | EYA3 2/4885TTR 1815/4885MEN1 2543/4885 |
| US-10221151-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | EYA2, EYA3, PTPRO | EYA3 2/4885TTR 1815/4885MEN1 2543/4885 |
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | EYA3, EYA2, LIG3 | EYA3 1/4885TTR 3493/4885MEN1 2596/4885 |
| US-20160052904-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | EYA2, EYA3, PTPRJ | EYA3 2/4885TTR 2631/4885MEN1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.